Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Ball who started this subject	3/8/2004 12:11:39 AM
From: mopgcw	of 496

Guilford Pharmaceuticals (GLFD-NNM) by IRG Research (7.93, Feb. 27) Initiating with Buy. Guilford's U.S. relaunch of Aggrastat could generate meaningful sales. The company acquired Aggrastat, a clinically proven treatment for acute coronary syndrome, from Merck (which had neglected the drug)....Aggrastat revenue could grow to $120 million in '07 from $26 million in '04. Our forecast takes into account a label expansion of the drug to include adjunct therapy with PCI, the standard surgical treatment for acute coronary syndrome. Aquavan, an anesthetic, could be approved in '06, launched in '07....Clearly, this is a positive development. Our price target is 12 based on a combination of product-pipeline and market-cap-to-sales analysis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next